Table 2 Tumor characteristics and treatment modalities of the entire cohort according to genotype (n = 180)
From: Hepatitis C virus genotype affects survival in patients with hepatocellular carcinoma
|  | Genotype 1 (n = 86) | Genotype 2 (n = 78) | Genotype 3 (n = 16) |
|---|---|---|---|
AFP, ng/mL | 19.9 (9.3–93.2) | 41.8 (8.4–100.2) b | 21.7 (7.3–72.9) |
Within Milan criteria | 53 (61.6%) | 52 (66.7%) | 8 (50.0%) |
Malignant vascular invasion | 7 (8.1%) | 4 (5.1%) b | 4 (25.0%) |
Extrahepatic metastasis | 3 (3.5%) | 1 (1.3%) | 2 (12.5%) |
HCC nodules | |||
 1 | 47 (54.7%) | 48 (61.5%) | 5 (31.3%) |
 2~3 | 19 (22.1%) | 21 (26.9%) | 6 (37.5%) |
 ≥ 4 | 20 (23.3%) | 9 (11.5%) | 5 (31.3%) |
Largest tumor size | |||
 < 2 cm | 27 (30.7%) | 21 (26.9%) | 6 (37.5%) |
 2 ~  5 cm | 41 (47.7%) | 45 (57.7%) | 5 (31.3%) |
 > 5 cm | 18 (20.9%) | 12 (15.4%) | 5 (31.3%) |
BCLC b c | |||
 0 | 15 (17.4%) | 10 (12.8%) | 1 (6.3%) |
 A | 41 (47.7%) | 46 (59.0%) | 7 (43.8%) |
 B | 19 (22.1%) | 14 (17.9%) | 1 (6.3%) |
 C | 10 (11.6%) | 5 (6.4%) | 5 (31.3%) |
 D | 1 (1.2%) | 3 (3.8%) | 2 (12.5%) |
mUICC b c | |||
 1 | 15 (17.4%) | 13 (16.7%) | 2 (12.5%) |
 2 | 39 (45.3%) | 39 (50.0%) | 8 (50.0%) |
 3 | 22 (25.6%) | 24 (30.8%) | 4 (25.0%) |
 4 | 10 (11.6%) | 2 (2.6%) | 2 (12.5%) |
Treatment modality | |||
 Resection | 17 (19.8%) | 23 (29.5%) | 1 (6.3%) |
 RFA | 23 (26.7%) | 19 (24.4%) b | 0 c |
 TACE | 58 (67.4%) a | 40 (51.3%) | 11 (68.8%) |
 PEI | 1 (1.2%) | 1 (1.3%) | 0 |
 Radiotherapy | 10 (11.6%) | 6 (7.7%) | 1 (6.3%) |
 Systemic chemotherapy | 2 (2.3%) | 1 (1.3%) | 0 |
 Sorafenib | 4 (4.7%) | 1 (1.3%) | 1 (6.3%) |
 Liver transplantation | 0 | 1 (1.3%) | 0 |
 No Treatment | 9 (10.5%) | 12 (15.4%) | 2 (12.5%) |
Curative Treatment (Initial) | 26 (33.7%) | 36 (46.2%) b | 1 (6.3%) c |
Recurrence after curative treatment (n = 66) | 20 (69.0%) | 21 (58.3%) | 1 (100%) |
Decompensation | 47 (54.7%) a | 22 (28.6%) b | 13 (81.3%) |
Death | 49 (57.0%) a | 29 (37.2%) b | 11 (68.8%) |